Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
BSX's Cash-to-Debt is ranked lower than
97% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. BSX: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
BSX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.17 Max: N/A
Current: 0.03
Equity-to-Asset 0.39
BSX's Equity-to-Asset is ranked lower than
82% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. BSX: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BSX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.51 Max: 0.83
Current: 0.39
0.18
0.83
Interest Coverage 2.23
BSX's Interest Coverage is ranked lower than
92% of the 225 Companies
in the Global Medical Devices industry.

( Industry Median: 77.23 vs. BSX: 2.23 )
Ranked among companies with meaningful Interest Coverage only.
BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.37  Med: 1.92 Max: 3.22
Current: 2.23
0.37
3.22
Piotroski F-Score: 6
Altman Z-Score: 2.00
Beneish M-Score: -2.54
WACC vs ROIC
7.37%
5.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 6.04
BSX's Operating Margin % is ranked higher than
59% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.31 vs. BSX: 6.04 )
Ranked among companies with meaningful Operating Margin % only.
BSX' s Operating Margin % Range Over the Past 10 Years
Min: -53.36  Med: -4.23 Max: 11.86
Current: 6.04
-53.36
11.86
Net Margin % 5.07
BSX's Net Margin % is ranked higher than
60% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.62 vs. BSX: 5.07 )
Ranked among companies with meaningful Net Margin % only.
BSX' s Net Margin % Range Over the Past 10 Years
Min: -56.12  Med: -4.56 Max: 5.79
Current: 5.07
-56.12
5.79
ROE % 6.60
BSX's ROE % is ranked higher than
61% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.67 vs. BSX: 6.60 )
Ranked among companies with meaningful ROE % only.
BSX' s ROE % Range Over the Past 10 Years
Min: -44.65  Med: -3.5 Max: 6.6
Current: 6.6
-44.65
6.6
ROA % 2.44
BSX's ROA % is ranked higher than
59% of the 336 Companies
in the Global Medical Devices industry.

( Industry Median: 0.13 vs. BSX: 2.44 )
Ranked among companies with meaningful ROA % only.
BSX' s ROA % Range Over the Past 10 Years
Min: -21.16  Med: -1.48 Max: 2.44
Current: 2.44
-21.16
2.44
ROC (Joel Greenblatt) % 28.98
BSX's ROC (Joel Greenblatt) % is ranked higher than
74% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. BSX: 28.98 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BSX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -144.7  Med: -14.88 Max: 32.39
Current: 28.98
-144.7
32.39
3-Year Revenue Growth Rate 4.60
BSX's 3-Year Revenue Growth Rate is ranked lower than
52% of the 243 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. BSX: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BSX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 4.6 Max: 29
Current: 4.6
-10.5
29
3-Year EBITDA Growth Rate 14.70
BSX's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. BSX: 14.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BSX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -71.1  Med: 14.7 Max: 271.1
Current: 14.7
-71.1
271.1
GuruFocus has detected 2 Warning Signs with Boston Scientific Corp $BSX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BSX's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:SYK, NAS:ALGN, NYSE:VAR, NYSE:TFX, NAS:ABMD, NAS:MASI, NAS:IART » details
Traded in other countries:BSX.Germany,
Headquarter Location:USA
Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Top Ranked Articles about Boston Scientific Corp

Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System
Boston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty
The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter Guru adds 3 positions and closes 3 others
Julian Robertson (Trades, Portfolio), founder of Tiger Management, invests with long-short strategies. During the first quarter, the guru added positions in Adobe Systems Inc. (NASDAQ:ADBE), Boston Scientific Corp. (NYSE:BSX) and JPMorgan Chase & Co. (NYSE:JPM). On the sell side, Robertson divested his holdings in HollyFrontier Corp. (NYSE:HFC), Apple Inc. (NASDAQ:AAPL) and Shire PLC (NASDAQ:SHPG). Read more...
Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device
New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints
Boston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective Study of 'Real-World' Patients
Boston Scientific Announces Schedule of Presentations at EuroPCR 2017
Boston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices
Boston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017

Ratios

vs
industry
vs
history
PE Ratio 87.35
BSX's PE Ratio is ranked lower than
85% of the 181 Companies
in the Global Medical Devices industry.

( Industry Median: 31.49 vs. BSX: 87.35 )
Ranked among companies with meaningful PE Ratio only.
BSX' s PE Ratio Range Over the Past 10 Years
Min: 13.87  Med: 38.21 Max: 404.33
Current: 87.35
13.87
404.33
Forward PE Ratio 22.27
BSX's Forward PE Ratio is ranked higher than
70% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 25.06 vs. BSX: 22.27 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 87.35
BSX's PE Ratio without NRI is ranked lower than
86% of the 180 Companies
in the Global Medical Devices industry.

( Industry Median: 31.49 vs. BSX: 87.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
BSX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.87  Med: 38.21 Max: 404.33
Current: 87.35
13.87
404.33
Price-to-Owner-Earnings 51.56
BSX's Price-to-Owner-Earnings is ranked lower than
66% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 37.06 vs. BSX: 51.56 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BSX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.58  Med: 45.08 Max: 985.26
Current: 51.56
11.58
985.26
PB Ratio 5.42
BSX's PB Ratio is ranked lower than
74% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. BSX: 5.42 )
Ranked among companies with meaningful PB Ratio only.
BSX' s PB Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.45 Max: 5.42
Current: 5.42
0.59
5.42
PS Ratio 4.47
BSX's PS Ratio is ranked lower than
64% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. BSX: 4.47 )
Ranked among companies with meaningful PS Ratio only.
BSX' s PS Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.22 Max: 4.47
Current: 4.47
1.02
4.47
Price-to-Free-Cash-Flow 70.58
BSX's Price-to-Free-Cash-Flow is ranked lower than
79% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 32.05 vs. BSX: 70.58 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BSX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.21  Med: 20.4 Max: 220
Current: 70.58
7.21
220
Price-to-Operating-Cash-Flow 39.48
BSX's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 136 Companies
in the Global Medical Devices industry.

( Industry Median: 20.42 vs. BSX: 39.48 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BSX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 15.78 Max: 62.72
Current: 39.48
5.75
62.72
EV-to-EBIT 89.78
BSX's EV-to-EBIT is ranked lower than
93% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 24.65 vs. BSX: 89.78 )
Ranked among companies with meaningful EV-to-EBIT only.
BSX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2577.3  Med: -3.9 Max: 25838
Current: 89.78
-2577.3
25838
EV-to-EBITDA 42.08
BSX's EV-to-EBITDA is ranked lower than
83% of the 186 Companies
in the Global Medical Devices industry.

( Industry Median: 18.57 vs. BSX: 42.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.7 Max: 242.5
Current: 42.08
-680.1
242.5
Current Ratio 0.87
BSX's Current Ratio is ranked lower than
89% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. BSX: 0.87 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.56 Max: 7.77
Current: 0.87
0.52
7.77
Quick Ratio 0.59
BSX's Quick Ratio is ranked lower than
90% of the 331 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. BSX: 0.59 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.2 Max: 6.29
Current: 0.59
0.33
6.29
Days Inventory 143.75
BSX's Days Inventory is ranked lower than
55% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. BSX: 143.75 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 113.61  Med: 133.18 Max: 164.78
Current: 143.75
113.61
164.78
Days Sales Outstanding 60.78
BSX's Days Sales Outstanding is ranked higher than
60% of the 282 Companies
in the Global Medical Devices industry.

( Industry Median: 68.69 vs. BSX: 60.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 60.78
58.51
66.79
Days Payable 54.85
BSX's Days Payable is ranked lower than
51% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 55.39 vs. BSX: 54.85 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 67.31
Current: 54.85
21.66
67.31

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.00
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
71% of the 230 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. BSX: -1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.9  Med: -1 Max: 4.6
Current: -1
-25.9
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.90
BSX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
62% of the 142 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. BSX: 2.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BSX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.51  Med: 1.52 Max: 500
Current: 2.9
0.51
500
Price-to-Median-PS-Value 2.01
BSX's Price-to-Median-PS-Value is ranked lower than
86% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. BSX: 2.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BSX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.47 Max: 4.29
Current: 2.01
0.48
4.29
Price-to-Peter-Lynch-Fair-Value 1.57
BSX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
99.99% of the 55 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. BSX: 1.57 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BSX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0  Med: 1.63 Max: 12.18
Current: 1.57
0
12.18
Earnings Yield (Greenblatt) % 1.12
BSX's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.12 vs. BSX: 1.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BSX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.3  Med: -1.4 Max: 9.1
Current: 1.12
-34.3
9.1
Forward Rate of Return (Yacktman) % 42.36
BSX's Forward Rate of Return (Yacktman) % is ranked higher than
96% of the 127 Companies
in the Global Medical Devices industry.

( Industry Median: 8.64 vs. BSX: 42.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BSX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.1  Med: 6.9 Max: 42.36
Current: 42.36
3.1
42.36

More Statistics

Revenue (TTM) (Mil) $8,582.00
EPS (TTM) $ 0.32
Beta0.93
Short Percentage of Float1.23%
52-Week Range $19.67 - 28.51
Shares Outstanding (Mil)1,369.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8,862 9,397 9,983
EPS ($) 1.25 1.40 1.56
EPS without NRI ($) 1.25 1.40 1.56
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.68%
Dividends per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 
Charles D. Christy Named Chief Financial Officer Jun 23 2017 
Harwood Feffer LLP Announces Investigation of CardConnect Corp. Jun 23 2017 
eCobalt Provides Feasibility Study Update on the Idaho Cobalt Project Jun 23 2017 
Tanger Outlet Centers Schedules Second Quarter 2017 Earnings Release and Conference Call Jun 23 2017 
Cortelco Systems Puerto Rico, Inc. Board of Directors Authorizes Dividend Jun 23 2017 
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Pr Jun 23 2017 
Allstate to Discuss Second Quarter 2017 Earnings With Investors Jun 23 2017 
"FCA Replay" Wraps the Week Jun 23 2017 
180 Degree Capital Corp.’s Portfolio Company, D-Wave Systems, and Their Work With Volkswagen Di Jun 23 2017 

More From Other Websites
Glassdoor: Apple CEO Tim Cook’s Employee Ranking Has Dropped Jun 21 2017
ETFs with exposure to Boston Scientific Corp. : June 19, 2017 Jun 19 2017
Boston Scientific Corp. :BSX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Boston Scientific Corporation -- Moody's assigns P-2 short term rating to Boston Scientific Jun 15 2017
Boston Scientific: We're always looking to add to portfol... Jun 15 2017
Why Boston Scientific Continues To Invest In Endoscopy Jun 13 2017
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised) Jun 07 2017
Boston Scientific Receives CE Mark for Vercise™ Gevia™ Deep Brain Stimulation System Jun 06 2017
[$$] Secondary Direct Manager Listings Jun 05 2017
Boston Scientific (BSX) Up 4.4% Since Earnings Report: Can It Continue? Jun 02 2017
Boston Scientific Trades Up on Strong Q1 amid Recall Issues May 30 2017
What Do Analysts Recommend for Boston Scientific? May 29 2017
BSX’s Resonate ICD and CRT-D Defibrillators Get US Approval May 29 2017
How Will the Lotus Recall Affect BSX’s 2017 Performance? May 29 2017
How BSX’s Lotus Recall Developments Impacted Its Share Price May 26 2017
Boston Scientific Completes Its Acquisition of Symetis May 26 2017
Discussing Boston Scientific Stock’s Recent Movements May 26 2017
St. Jude Medical May Establish ABT as a Key Medical Device Player May 26 2017
Analysts’ Recommendations for Abbott Laboratories in May 2017 May 25 2017
Is Medical Technology Driving the US Healthcare Industry? May 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}